The most recent trading session ended with Gilead Sciences (GILD) standing at $91.41, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Following its massive success with hepatitis C drugs Sovaldi and Harvoni, everyone has been watching Gilead closely to see how it will try to sustain its stratospheric growth. It was already clear ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...

Gilead Sciences' chief medical officer, Merdad Parsey, will leave the company in early 2025, becoming the latest in a series of high-profile departures involving senior R&D figures at top drugmakers.

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers, paving the ...

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...